Glenmark  receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules

0 101,072

Mumbai : Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, the generic version of Taytulla®1 Capsules, of Allergan Pharmaceuticals International Limited. According to IQVIATM sales data for the 12 month period ending May 2022, the Taytulla® Capsules market2 achieved annual sales of approximately $85.9 million*. Glenmark’s current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Leave A Reply

Your email address will not be published.